Neurelis Inc Drug Patent Portfolio
Neurelis Inc owns 1 orange book drug protected by 7 US patents Given below is the list of Neurelis Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11241414 | Administration of benzodiazepine compositions | 27 Mar, 2029 | Active |
| US11793786 | Administration of benzodiazepine compositions | 27 Mar, 2029 | Active |
| US8895546 | Administration of benzodiazepine compositions | 27 Mar, 2029 | Active |
| US9763876 | Administration of benzodiazepine compositions | 27 Mar, 2029 | Active |
| US8927497 | Absorption enhancers for intranasal administration | 21 Jul, 2025 | Active |
| US10265402 | Absorption enhancers for drug administration | 11 May, 2025 | Active |
| US9642913 | Pharmaceutical composition including alkyl glycoside and an anti-seizure agent | 11 May, 2025 | Active |
Latest Legal Activities on Neurelis Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Neurelis Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Recordation of Patent Grant Mailed
Critical
| 24 Oct, 2023 | US11793786 |
|
Email Notification
Critical
| 24 Oct, 2023 | US11793786 |
| Mail Patent eGrant Notification | 24 Oct, 2023 | US11793786 |
| Recordation of Patent eGrant | 24 Oct, 2023 | US11793786 |
| Patent eGrant Notification | 24 Oct, 2023 | US11793786 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 24 Oct, 2023 | US11793786 |
|
Email Notification
Critical
| 05 Oct, 2023 | US11793786 |
|
Issue Notification Mailed
Critical
| 04 Oct, 2023 | US11793786 |
| Dispatch to FDC | 19 Sep, 2023 | US11793786 |
|
Application Is Considered Ready for Issue
Critical
| 19 Sep, 2023 | US11793786 |
| Miscellaneous Incoming Letter | 13 Sep, 2023 | US11793786 |
|
Issue Fee Payment Verified
Critical
| 13 Sep, 2023 | US11793786 |
|
Issue Fee Payment Received
Critical
| 13 Sep, 2023 | US11793786 |
|
Email Notification
Critical
| 29 Aug, 2023 | US11793786 |
| Mail Examiner Interview Summary (PTOL - 413) | 29 Aug, 2023 | US11793786 |
Neurelis Inc's Drug Patent Litigations
Neurelis Inc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 29, 2019, against patent number US9763876. The petitioner Aquestive Therapeutics, Inc. formerly Monosol RX, LLC, challenged the validity of this patent, with Neurelis, Inc. as the respondent. Click below to track the latest information on how companies are challenging Neurelis Inc's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9763876 | January, 2019 |
FWD Entered
(06 Aug, 2020)
| Neurelis, Inc. | Aquestive Therapeutics, Inc. formerly Monosol RX, LLC |
| US9763876 | January, 2019 |
Terminated-Denied
(01 Aug, 2019)
| Neurelis, Inc. | Aquestive Therapeutics, Inc. formerly Monosol RX, LLC |
| US9763876 | January, 2019 |
Terminated-Denied
(01 Aug, 2019)
| Neurelis, Inc. | Aquestive Therapeutics, Inc. formerly Monosol RX, LLC |
Neurelis Inc's Family Patents
Neurelis Inc Drug List
Given below is the complete list of Neurelis Inc's drugs and the patents protecting them.
1. Valtoco
Valtoco is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11241414 | Administration of benzodiazepine compositions |
27 Mar, 2029
(4 years from now)
| Active |
| US11793786 | Administration of benzodiazepine compositions |
27 Mar, 2029
(4 years from now)
| Active |
| US8895546 | Administration of benzodiazepine compositions |
27 Mar, 2029
(4 years from now)
| Active |
| US9763876 | Administration of benzodiazepine compositions |
27 Mar, 2029
(4 years from now)
| Active |
| US8927497 | Absorption enhancers for intranasal administration |
21 Jul, 2025
(8 months from now)
| Active |
| US10265402 | Absorption enhancers for drug administration |
11 May, 2025
(5 months from now)
| Active |
| US9642913 | Pharmaceutical composition including alkyl glycoside and an anti-seizure agent |
11 May, 2025
(5 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Valtoco's drug page